Skip to content
AwardedCzechiaGoodsCZK 141,891,000

Antivirotika HCV – Sofosbuvir - Velpatasvir - II.

Published
Published 13 April 2026
Deadline
Closed 12 May 2026

Overview

The Institut klinické a experimentální medicíny (Institute of Clinical and Experimental Medicine) procured antiviral medications containing sofosbuvir and velpatasvir (ATC J05AP55) for treating patients in approved indications. Gilead Sciences s.r.o. was awarded the contract on 14 May 2026 for 141,890,448.7 CZK.

Key details

Country
Czechia
Status
Awarded
Category
Goods
Estimated value
CZK 141,891,000
Procedure
Open
Published
13 April 2026
Deadline
Closed
Classification (CPV)
Antivirals for systemic use

Award outcome

Awarded value
CZK 141,890,449
Award date
14 May 2026
Contract period
— → 23 April 2030
Winner
  • Gilead Sciences s.r.o.

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    3 June 2026

  2. Contract Notice

    13 April 2026

Contracting authority

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Antivirotika HCV – Sofosbuvir - Velpatasvir - II. — won by Gilead Sciences s.r.o. — Skim